'The Top Line': Will Eisai's Alzheimer's med lecanemab sway the CMS, how Pfizer is upping its DTC ad push for its COVID shots
Eisai and Biogen’s Alzheimer’s disease drug lecanemab did surprisingly well in a phase 3 trial. | This week on “The Top Line,” we talk about trial results for Eisai and Biogen’s Alzheimer’s drug, which were surprisingly good, and we dig into what comes next. We also discuss how Pfizer is ramping up its DTC ad campaign for its COVID shots, most recently spending big on a booster ad for the NFL season.
